Kyowa Kirin Co.,Ltd. Logo

Kyowa Kirin Co.,Ltd.

Develops antibody medicines for oncology, nephrology, immunology, and allergy.

4151 | T

Overview

Corporate Details

ISIN(s):
JP3256000005
LEI:
Country:
Japan
Address:
千代田区大手町一丁目9番2号
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Kyowa Kirin is a global specialty pharmaceutical company dedicated to addressing unmet medical needs through innovative drug discovery. The company engages in the research, development, manufacturing, and commercialization of pharmaceuticals and biotechnology products. Focusing on core therapeutic areas such as nephrology, oncology, immunology, and allergy, Kyowa Kirin leverages its advanced antibody technologies to create novel medicines. Guided by its mission of "Commitment to Life," the organization strives to deliver life-changing value to patients, their families, and medical professionals worldwide by developing and marketing innovative prescription drugs that contribute to global health and well-being.

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-07-31 08:30
Interim Report
半期報告書-第103期(2025/01/01-2025/12/31)
Japanese 991.7 KB
2025-07-31 08:30
Report Publication Announcement
確認書
Japanese 8.1 KB
2025-07-11 09:30
Regulatory News Service
臨時報告書
Japanese 21.2 KB
2025-03-21 06:47
Registration Form
訂正有価証券届出書(参照方式)
Japanese 46.5 KB
2025-03-21 06:41
Post-Annual General Meeting Information
臨時報告書
Japanese 26.8 KB
2025-03-19 07:51
Registration Form
有価証券届出書(参照方式)
Japanese 56.3 KB
2025-03-11 07:31
Annual Report
有価証券報告書-第102期(2024/01/01-2024/12/31)
Japanese 4.0 MB
2025-03-11 07:31
Governance Information
内部統制報告書-第102期(2024/01/01-2024/12/31)
Japanese 22.5 KB
2025-03-11 07:31
Registration Form
確認書
Japanese 8.2 KB
2024-11-14 07:30
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 26.6 KB
2024-10-31 07:30
Board/Management Information
臨時報告書
Japanese 26.1 KB
2024-10-11 08:30
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 24.9 KB
2024-09-12 08:32
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 28.2 KB
2024-08-09 08:30
Transaction in Own Shares
自己株券買付状況報告書(法24条の6第1項に基づくもの)
Japanese 26.1 KB
2024-08-01 08:31
Interim Report
半期報告書-第102期(2024/01/01-2024/12/31)
Japanese 916.7 KB

Automate Your Workflow. Get a real-time feed of all Kyowa Kirin Co.,Ltd. filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for Kyowa Kirin Co.,Ltd.

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for Kyowa Kirin Co.,Ltd. via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
No insider transactions recorded for this company.

Peer Companies

MADRIGAL PHARMACEUTICALS, INC. Logo
Develops and delivers the first FDA-approved treatment for the liver disease MASH.
United States of America
MDGL
Magle Chemoswed Holding AB Logo
A CDMO for pharma/med device firms, offering end-to-end development and specialized manufacturing.
Sweden
MAGLE
Develops at-home diagnostic tests for the early detection of life-threatening cancers.
Germany
MYNZ
MANNKIND CORP Logo
Develops inhaled therapies for endocrine, orphan lung, and cardiometabolic diseases.
United States of America
MNKD
MARAVAI LIFESCIENCES HOLDINGS, INC. Logo
Provides nucleic acid products and biologics safety testing for new therapies and vaccines.
United States of America
MRVI
Marinomed Biotech AG Logo
Develops virus-blocking products & immunology therapies via proprietary technology platforms.
Austria
MARI
Marker Therapeutics, Inc. Logo
Developing non-genetically modified T cell immunotherapies for hematologic and solid tumors.
United States of America
MRKR
Matinas BioPharma Holdings, Inc. Logo
Developing oral drugs via a lipid nano-crystal platform for infections, oncology & inflammation.
United States of America
MTNB
Matricelf Ltd. Logo
Develops personalized 3D neural implants from patient cells to treat spinal cord injuries.
Israel
MTLF
Maze Therapeutics, Inc. Logo
Develops genetic precision medicines for common diseases, with a focus on chronic kidney disease.
United States of America
MAZE

Talk to a Data Expert

Have a question? We'll get back to you promptly.